Wegovy 25mg GLP-1 Pill, 30 Tablets, for Weight Loss Support

Wegovy 25mg Tablets are a prescription-only, once-daily oral GLP-1 receptor agonist treatment containing semaglutide, developed by Novo Nordisk to support adults living with obesity or overweight with weight-related health conditions. Designed for long-term weight management, Wegovy® Pill works alongside a balanced diet and increased physical activity to help achieve clinically proven and sustainable weight loss. Containing semaglutide, a molecule supported by more than eight years of clinical studies and real-world experience, Wegovy® Pill works with the body's natural mechanisms by reducing appetite, increasing feelings of fullness, and helping individuals eat less over time. Its established safety profile and extensive clinical evidence provide confidence in long-term use under healthcare professional supervision

The 25mg strength is the recommended maintenance dose following the gradual dose-escalation phases of 1.5mg, 4mg, and 9mg. The convenient once-daily tablet format offers an alternative to injectable GLP-1 therapies, making it suitable for individuals who prefer oral treatment. Taken in the morning on an empty stomach with a sip of water and followed by a 30-minute wait before eating or drinking, Wegovy® Pill fits seamlessly into everyday routines and supports ongoing adherence to healthy lifestyle habits. Clinical studies cited by the manufacturer demonstrated meaningful weight loss, with an average reduction of approximately 17%, while around one-third of participants achieved weight loss of 20% or more.

Benefits

• Contains semaglutide, a GLP-1 receptor agonist with over 8 years of clinical experience.
• Once-daily tablet format provides an alternative to injectable GLP-1 therapies.
• Works with the body's natural mechanisms to reduce appetite and enhance feelings of fullness.
• Designed to support clinically proven, gradual, and sustainable weight management.
• Can be incorporated into a simple morning routine.
• Intended for long-term use as part of a medical weight management program.
• No injections required, making administration convenient for those with an oral preference.
• Clinical studies reported average weight reduction of approximately 17%, with some participants achieving 20% or greater weight loss.
• Established safety profile consistent with the GLP-1 receptor agonist class.

Suggested Usage : Wegovy 25mg Tablets should be used only as prescribed by a healthcare professional. Take one tablet once daily in the morning on an empty stomach with up to half a cup of water. Wait at least 30 minutes before eating, drinking, or taking other oral medications. The 25mg strength is the maintenance dose reached after completing the recommended dose-escalation schedule and should be continued according to your healthcare provider's instructions.

Suitable For

• Adults aged 18 years and above.
• Individuals living with obesity.
• Adults who are overweight and have weight-related health conditions.
• People who prefer oral tablets over injectable treatments.
• Individuals seeking a physician-supervised weight management approach.
• Those committed to combining treatment with balanced nutrition and increased physical activity.
• Not suitable for individuals with hypersensitivity to semaglutide or any formulation components.

Product Specifications